Login / Signup

Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel Disease.

David K ChoiArchariya PuangampaiDavid T Rubin
Published in: The Annals of pharmacotherapy (2022)
Keyphrases
  • patients with inflammatory bowel disease
  • open label
  • metabolic syndrome
  • clinical trial
  • randomized controlled trial
  • adipose tissue
  • insulin resistance
  • study protocol